AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Show more

1 North Waukegan Road, North Chicago, IL, 60064-6400, United States

https://www.abbvie.com

Drug Manufacturers - General

Healthcare

Start AI Chat

Market Cap

394.1B

52 Wk Range

$181.73 - $244.81

Previous Close

$223.07

Open

$224.80

Volume

4,060,335

Day Range

$221.72 - $227.14

Enterprise Value

460.9B

Cash

9.391B

Avg Qtr Burn

N/A

Insider Ownership

0.11%

Institutional Own.

76.91%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BOTOX Cosmetic/OnabotulinumtoxinA (N/A) (Neuromuscular Blocker) Details Moderate To Severe Glabellar Lines	Phase 4 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RINVOQ/Upadacitinib (ABT-494) (JAK1 Inhibitor) Details Moderate To Severe Rheumatoid Arthritis After TNF Inhibitor Failure	Phase 4 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SKYRIZI/Risankizumab (N/A) (IL-23 Inhibitor) Details Psoriatic Arthritis	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rinvoq/Upadacitinib (ABT-494) (JAK1 Inhibitor) Details Crohn's Disease	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RINVOQ/Upadacitinib (ABT-494) (JAK1 Inhibitor) Details Moderate To Severe Rheumatoid Arthritis	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RINVOQ/Upadacitinib (ABT-494) (JAK1 Inhibitor) Details Atopic Dermatitis	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rinvoq/Upadacitinib (ABT-494) (JAK1 Inhibitor) Details Ulcerative Colitis	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pivekimab sunirine (PVEK) Details Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Skyrizi/Risankizumab (N/A) (IL-23 Inhibitor) Details Ulcerative Colitis	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SKYRIZI/Risankizumab (N/A) (IL-23 Inhibitor) Details Genital And Scalp Psoriasis	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RINVOQ (upadacitinib) Details Giant Cell Arteritis (GCA)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EPKINLY® (epcoritamab-bysp) + rituximab and lenalidomide Details Relapsed or refractory follicular lymphoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VENCLEXTA® (venetoclax) + Acalabrutinib Details Chronic Lymphocytic Leukemia (CLL)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EMRELIS™ (telisotuzumab vedotin-tllv) Details NSCLC With High c-Met Protein Overexpression	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SKYRIZI/Risankizumab (N/A) (IL-23 Inhibitor) Details Crohn's Disease	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RINVOQ (upadacitinib) Details Alopecia areata	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RINVOQ/Upadacitinib (ABT-494) (JAK1 Inhibitor) Details Non-Segmental Vitiligo (NSV)	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tavapadon Details Parkinson's disease, Brain disease	NDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EPKINLY/Epcoritamab-bysp (GEN3013) (CD3xCD20 Bispecific) Details Relapsed Or Refractory Diffuse Large B-Cell Lymphoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tavapadon (adjunct with L-Dopa) Details Parkinson's disease, Brain disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atogepant (QULIPTA® / AQUIPTA®) Details Migraine Prevention	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details EGFR-Mutated Non-Small Cell Lung Cancer	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-706 (SEZ6 ADC) Details Extensive-Stage Small Cell Lung Cancer	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Temab-A/Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CVL-871 (D1/D5 partial antagonist) Details Dementia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OnabotulinumtoxinA (BOTOX®) Details Upper Limb Essential Tremor	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Emraclidine (CVL-231) Details Brain disease, Schizophrenia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Darigabat (CVL-865) Details Epilepsy	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NX-13 Details Ulcerative colitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Darigabat Details Social Anxiety Disorder, Panic Disorder	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elahere/Mirvetuximab Soravtansine-Gynx (N/A) (FRα ADC) Details FRα-Expressing Advanced-Stage Serous Epithelial Ovarian Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elahere/Mirvetuximab Soravtansine (N/A) (FRα ADC) Details FRα-Expressing Advanced-Stage Serous Epithelial Ovarian Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details Unresectable Or Metastatic Non-Small Cell Lung Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Temab-A/Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details Unresectable Or Metastatic Non-Small Cell Lung Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Temab-A/Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details Circulating Tumor DNA-Positive Colorectal Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Temab-A/Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details MET-Amplified Advanced Solid Tumors	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details Advanced Solid Tumors With MET Amplification	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details Circulating Tumor DNA-Positive Colorectal Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etentamig (ABBV-383) (BCMAxCD3 Bispecific) Details Relapsed Or Refractory Light Chain Amyloidosis	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etentamig (N/A) (BCMAxCD3 Bispecific) Details Relapsed Or Refractory Multiple Myeloma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etentamig (BCMA-CD3 Engager) Details Relapsed Or Refractory Multiple Myeloma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-706 (SEZ6 ADC) Details Small Cell Lung Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details Platinum-Resistant Ovarian Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Temab-A/Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details Head And Neck Squamous Cell Carcinoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Emraclidine (CVL-231) Details Brain disease, Neurodegenerative disease, Alzheimer's disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-969 (Bispecific ADC) Details Metastatic Castration-Resistant Prostate Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-706 (SEZ6 ADC) Details High-Grade Central Nervous System Tumors	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-969 (PSMA-STEAP1 ADC) Details Metastatic Castration-Resistant Prostate Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-295 (GUB014295) (Amylin Receptor Agonist) Details Obesity (Chronic Weight Management)	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CVL-354 Details Major depressive disorder	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-295 (Amylin Analog) Details Obesity (Chronic Weight Management)	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Temab-A/Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details Platinum-Resistant Ovarian Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Telisotuzumab Adizutecan (ABBV-400) (c-Met ADC) Details Head And Neck Squamous Cell Carcinoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-706 (SEZ6 ADC) Details High-Grade Central Nervous System Tumors	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-706 (SEZ6 ADC) Details Relapsed Or Refractory Small Cell Lung Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Venetoclax + Azacitidine Details Higher-risk myelodysplastic syndrome (HR-MDS)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.